George B. Abercrombie serves as Independent Director of the Company. Mr. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. Mr. Abercrombie held the position of Senior Vice President and Chief Commercial Officer at Innoviva, Inc., a publicly traded bio-pharmaceutical asset management company, from 2014 to 2018. He served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible leading operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie also serves on the Board of Brickell Biotech, a private pharmaceutical company. He formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc., Ziopharm Oncology, Inc, Tranzyme Pharma, Aptus Health, Inc. and DemeRX. Additionally, he is an Adjunct Professor at Duke University’s Fuqua School of Business and a board member of the North Carolina GlaxoSmithKline Foundation. He previously served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Pub.
What is George B. Abercrombie's net worth?
The estimated net worth of George B. Abercrombie is at least $67,959.01 as of May 24th, 2021. Mr. Abercrombie owns 9,667 shares of BioCryst Pharmaceuticals stock worth more than $67,959 as of November 17th. This net worth approximation does not reflect any other investments that Mr. Abercrombie may own. Learn More about George B. Abercrombie's net worth.
How do I contact George B. Abercrombie?
Has George B. Abercrombie been buying or selling shares of BioCryst Pharmaceuticals?
George B. Abercrombie has not been actively trading shares of BioCryst Pharmaceuticals during the past quarter. Most recently, George B. Abercrombie sold 5,000 shares of the business's stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $18.50, for a transaction totalling $92,500.00. Learn More on George B. Abercrombie's trading history.
Who are BioCryst Pharmaceuticals' active insiders?
Are insiders buying or selling shares of BioCryst Pharmaceuticals?
During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company.
Learn More about insider trades at BioCryst Pharmaceuticals. Information on this page was last updated on 6/24/2024.
